1.Knockdown of Bcl-xL Enhances Growth-Inhibiting and Apoptosis-Inducing Effects of Resveratrol and Clofarabine in Malignant Mesothelioma H-2452 Cells.
Yoon Jin LEE ; In Sung HWANG ; Yong Jin LEE ; Chang Ho LEE ; Sung Ho KIM ; Hae Saeon NAM ; Young Jin CHOI ; Sang Han LEE
Journal of Korean Medical Science 2014;29(11):1464-1472
Mcl-1 and Bcl-xL, key anti-apoptotic proteins of the Bcl-2 family, have attracted attention as important molecules in the cell survival and drug resistance. In this study, we investigated whether inhibition of Bcl-xL influences cell growth and apoptosis against simultaneous treatment of resveratrol and clofarabine in the human malignant mesothelioma H-2452 cells. Resveratrol and clofarabine decreased Mcl-1 protein levels but had little effect on Bcl-xL levels. In the presence of two compounds, any detectable change in the Mcl-1 mRNA levels was not observed in RT-PCR analysis, whereas pretreatment with the proteasome inhibitor MG132 led to its accumulation to levels far above basal levels. The knockdown of Bcl-xL inhibited cell proliferation with cell accumulation at G2/M phase and the appearance of sub-G0/G1 peak in DNA flow cytometric assay. The suppression of cell growth was accompanied by an increase in the caspase-3/7 activity with the resultant cleavages of procaspase-3 and its substrate poly (ADP-ribose) polymerase, and increased percentage of apoptotic propensities in annexin V binding assay. Collectively, our data represent that the efficacy of resveratrol and clofarabine for apoptosis induction was substantially enhanced by Bcl-xL-lowering strategy in which the simultaneous targeting of Mcl-1 and Bcl-xL could be a more effective strategy for treating malignant mesothelioma.
Adenine Nucleotides/*pharmacology
;
Antimetabolites, Antineoplastic/*pharmacology
;
Apoptosis/*drug effects
;
Arabinonucleosides/*pharmacology
;
Caspase 3/metabolism
;
Caspase 7/metabolism
;
Cell Line, Tumor
;
Cell Proliferation/drug effects
;
G2 Phase Cell Cycle Checkpoints/drug effects
;
Gene Knockdown Techniques
;
Humans
;
Leupeptins/pharmacology
;
Lung Neoplasms/metabolism/pathology
;
M Phase Cell Cycle Checkpoints/drug effects
;
Mesothelioma/metabolism/pathology
;
Myeloid Cell Leukemia Sequence 1 Protein/antagonists & inhibitors/genetics/metabolism
;
RNA Interference
;
RNA, Messenger/metabolism
;
RNA, Small Interfering/metabolism
;
Stilbenes/*pharmacology
;
bcl-X Protein/antagonists & inhibitors/*genetics/*metabolism